Literature DB >> 19683776

[Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease].

C Ardouin1, I Chéreau, P-M Llorca, E Lhommée, F Durif, P Pollak, P Krack.   

Abstract

The common perception that Parkinson's disease patients tend to be depressed, anxious, apathetic and harm-avoiding has currently been challenged by the recognition that they can also exhibit a hedonistic, novelty-seeking personality. Thus, Parkinson's disease patients may indulge in their passions in an irresponsible and disinhibited manner, and engage in repetitive, compulsive behaviors that may be harmful and destructive to their social or professional lives. The dopamine dysregulation syndrome includes hypersexuality, pathological gambling, and compulsive shopping; it is associated with addiction to dopaminergic medication. However, not all behavioral changes are necessarily accompanied by a dopaminergic addiction. After antiparkinson treatment is initiated, patients enter a 'honeymoon period' during which changes in mood and behavior reflect a return to the patients' premorbid personality. The increased motivation and higher level of activity in professional as well as leisure activities are considered positive changes by both the patients and their relatives. With prolonged and increased dopaminergic treatment, these positive behavioral changes can become excessive and evolve into nocturnal hyperactivity and stereotyped, repetitive and time consuming behaviors which ultimately disorganize the patient's everyday routine and herald behavioral addictions. These drug-induced behavioral changes are under-appreciated by neurologists and under-reported by the patients who neither complain about the behaviors nor understand the relationship between motivated behavior and dopaminergic medication. For these reasons, we propose a new scale for the assessment of behavior and mood to quantify and track changes related to Parkinson's disease, to dopaminergic medication, and to non-motor fluctuations. This scale is based on the concept of hypo- and hyperdopaminergic mood and behavior. The scale consists of 18 items addressing non-motor symptoms, grouped in four parts: general psychological evaluation, apathy, non-motor fluctuations and hyperdopaminergic behaviors. The rating in five points (0-4 from absent to severe) is carried out during a semi-structured interview. Open-ended questions introduce each item, allowing patients to express themselves as freely as possible. Close-ended questions permit the rating of severity and intensity. This new instrument can be used by psychologists, psychiatrists or neurologists familiar with Parkinson's disease. Designed to detect changes in mood and behavior of Parkinson's disease patients resulting either from the disease or its treatment, this tool can be used in conjunction with the neurocognitive evaluation, to help tailor the treatment of motor and non-motor symptoms to each individual's needs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19683776     DOI: 10.1016/j.neurol.2009.06.003

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  20 in total

Review 1.  Genetics of impulse control disorders in Parkinson's disease.

Authors:  Florence Cormier; Julia Muellner; Jean-Christophe Corvol
Journal:  J Neural Transm (Vienna)       Date:  2012-12-12       Impact factor: 3.575

2.  Course of psychiatric symptoms and global cognition in early Parkinson disease.

Authors:  Patricia de la Riva; Kara Smith; Sharon X Xie; Daniel Weintraub
Journal:  Neurology       Date:  2014-08-15       Impact factor: 9.910

Review 3.  Sleep in Parkinson's Disease with Impulse Control Disorder.

Authors:  Michela Figorilli; Patrizia Congiu; Rosa Lecca; Gioia Gioi; Roberto Frau; Monica Puligheddu
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-11       Impact factor: 5.081

4.  Executive functioning and risk-taking behavior in Parkinson's disease patients with impulse control disorders.

Authors:  Fanny Pineau; Emmanuel Roze; Lucette Lacomblez; Anne-Marie Bonnet; Marie Vidailhet; Virginie Czernecki; Jean-Christophe Corvol
Journal:  J Neural Transm (Vienna)       Date:  2016-04-16       Impact factor: 3.575

5.  A short scale for evaluation of neuropsychiatric disorders in Parkinson's disease: first psychometric approach.

Authors:  Pablo Martinez-Martin; Belen Frades-Payo; Luis Agüera-Ortiz; Angel Ayuga-Martinez
Journal:  J Neurol       Date:  2012-04-18       Impact factor: 4.849

6.  Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.

Authors:  Sophie Drapier; Alexandre Eusebio; Bertrand Degos; Marc Vérin; Franck Durif; Jean Philippe Azulay; François Viallet; Tiphaine Rouaud; Caroline Moreau; Luc Defebvre; Valerie Fraix; Christine Tranchant; Karine Andre; Christine Brefel Courbon; Emmanuel Roze; David Devos
Journal:  J Neurol       Date:  2016-04-08       Impact factor: 4.849

7.  The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.

Authors:  Emma Biondetti; Mathieu D Santin; Romain Valabrègue; Graziella Mangone; Rahul Gaurav; Nadya Pyatigorskaya; Matthew Hutchison; Lydia Yahia-Cherif; Nicolas Villain; Marie-Odile Habert; Isabelle Arnulf; Smaranda Leu-Semenescu; Pauline Dodet; Miquel Vila; Jean-Christophe Corvol; Marie Vidailhet; Stéphane Lehéricy
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

8.  The Neuropsychiatric Fluctuations Scale for Parkinson's Disease: A Pilot Study.

Authors:  Emmanuelle Schmitt; Paul Krack; Anna Castrioto; Helene Klinger; Amelie Bichon; Eugénie Lhommée; Pierre Pelissier; Valerie Fraix; Stephane Thobois; Elena Moro; Pablo Martinez-Martin
Journal:  Mov Disord Clin Pract       Date:  2018-03-23

9.  Diagnosis and treatment of impulse control disorders in patients with movement disorders.

Authors:  Tiago A Mestre; Antonio P Strafella; Teri Thomsen; Valerie Voon; Janis Miyasaki
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

10.  Long-term effect of apomorphine infusion in advanced Parkinson's disease: a real-life study.

Authors:  Bruna Meira; Bertrand Degos; Elise Corsetti; Mohamed Doulazmi; Emeline Berthelot; Clara Virbel-Fleischman; Pauline Dodet; Aurélie Méneret; Louise-Laure Mariani; Cécile Delorme; Florence Cormier-Dequaire; David Bendetowicz; Nicolas Villain; Clément Tarrano; Lise Mantisi; Hélène Letrillart; Céline Louapre; Eavan McGovern; Yulia Worbe; David Grabli; Marie Vidailhet; Elodie Hainque; Emmanuel Roze
Journal:  NPJ Parkinsons Dis       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.